Pure Global AI
NCT06364917Not yet recruiting

DISCERN: Dual Versus Single ICB in PDL-1 Negative NSCLC

DISCERN: Dual Immune Strategy Versus Single Checkpoint Inhibition Efficacy Response in PDL-1 Negative Non-Small Cell Lung Cancer (NSCLC)
University of Alabama at BirminghamPhase 2ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Non Small Cell Lung Cancer
Drug/Device/Intervention
Pembrolizumab
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Alabama at Birmingham
Location
Birmingham, United States of America
Timeline & enrollment
Phase
Phase 2
Start date
Oct 31, 2024
End date
Jun 01, 2027
Enrollment
24 participants
Primary outcome

Rate of Molecular Response in Patients with PD-L1 Negative Advanced NSCLC Treated with Dual vs. Single ICB Plus CT Regimens

Summary

The purpose of this study, known as DISCERN, is to compare two different treatments for a
 type of lung cancer called non-small cell lung cancer (NSCLC) that does not show a marker
 known as PD-L1. This study will help us understand if using two types of immune therapy
 together with chemotherapy is better than using one type of immune therapy with chemotherapy.
 We're doing this by looking at changes in the subject's cancer's DNA in the blood after
 starting treatment.

ICD-10 classifications
Secondary malignant neoplasm of lungMalignant neoplasm: Lower lobe, bronchus or lungMalignant neoplasm: Middle lobe, bronchus or lungMalignant neoplasm: Bronchus or lung, unspecifiedMalignant neoplasm of bronchus and lung
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06364917
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06364917 through Pure Global AI's free database. This Phase 2 trial is sponsored by University of Alabama at Birmingham and is currently Not yet recruiting. The study focuses on Non Small Cell Lung Cancer. Target enrollment is 24 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.